CRANBURY, N.J., Sept. 20 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced that studies of the mechanism of action of its investigational treatment for Gaucher disease were published in the September 12 edition of the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
